March 2017 Newsletter

March 23, 2017:

Growth in IVT Injections Boosts US Ophthalmic Procedures 12.6 Percent in Q4-2016

For the full year 2016, surgery volume rose 6.6 percent over the 2015 total.

March 23, 2017:

Repurposing Drugs for Ophthalmic Use Showcased at Annual Meeting of All India Ophthalmological Society

Conference drew 7 thousand ophthalmologists to colorful Jaipur, India.

March 23, 2017:

Calhoun Vision Becomes RxSight to Better Convey Mission to Transform Cataract Surgery

Company says its adjustable IOL will improve refractive precision.

March 23, 2017:

Allergan, Editas Sign Deal to Co-develop CRISPR Technology for Eye Disease

The move follows a Feb. 15 ruling in a US patent dispute that bolstered Editas’ position in the race to develop CRISPR.

March 23, 2017:

J&J Vision is New Name for Abbott Medical Optics

Tom Frinzi will continue to lead J&J Vision’s surgical division in Santa Ana, California.

March 23, 2017:

Knee Injections Create Significant Increase in IOP, Orthopedic Surgeon Reports

Subset of patients experienced average increase in IOP from 18 mmHg to 33 mmHg at one week.

March 23, 2017:

China’s Aier Eye Hospital Group Plans to Operate US Clinics

Aier is the largest eye hospital chain in China, operating 100 free-standing eye hospitals.

March 23, 2017:

Himalayan Cataract Project is Semifinalist for $100 Million Grant

The competition is designed to fund a project that makes measurable progress toward solving a significant global problem.

March 23, 2017:

First Allergan/AqueSys XEN Implanted in US Following FDA Approval

Thirty US glaucoma specialists are now using the gel stent in advanced glaucoma patients.

March 23, 2017:

Carl Zeiss Meditec: Jon Dishler, MD, Performed First US ReLEx SMILE Procedure

Worldwide, SMILE has been performed more than 700 thousand times since its introduction in 2011, the company says.

March 23, 2017:

Bausch + Lomb’s 2016 Revenues Account for Nearly Half of Valeant’s Total Revenues

Valeant expects 5 to 7 percent growth for its eye care segment in 2017.

March 23, 2017:

Bill Ackman of Pershing Square Sells His Position in Valeant

The hedge fund manager will not stand for re-election on Valeant's board.

March 23, 2017:

Shire’s Xiidra Dry Eye Treatment Earns $54 Million in Sales in 2016

The company credits marketing program with raising awareness of disease, drawing new patients.

March 23, 2017:

Q4-2016 Earnings Reports as of March 2017

This month's roundup covers Glaukos, Alimera Sciences, Aerie Pharmaceuticals, Second Sight, TearLab, and Ophthotech.

March 23, 2017:

Valeant Licenses EyeGate’s Delivery System and EGP-437 for Postoperative Pain, Inflammation

Eyegate received an upfront cash payment; the amount was not disclosed.

March 23, 2017:

Market Report: Surgeons’ Expanding Needs for Retinal Devices to Fuel Revenue Growth

The segment is expected to total more than $1.9 billion in 2017.

March 23, 2017:

Clearside Redirects Resources From Axitinib to Zuprata

Axitinib targets VEGF and PDGF receptors and was the firm's lead candidate for wet AMD.

March 23, 2017:

Ohr Pauses Enrollment in Phase III Trial of Squalamine

In 2016, the firm closed a public offering that raised nearly $7.8 million.

March 23, 2017:

Virginia Law Keeps Door Open for Online Eye Exams, Seeks to Protect Patients

Legislation receives support from optometrists and Opternative.

March 23, 2017:

US Astronaut Scott Kelly Will Deliver Major Lecture at 2017 ASCRS Meeting

March 23, 2017:

Imprimis Pharmaceuticals Begins Dispensing from FDA-Registered 503B Outsourcing Facility

Customers will no longer need specific patient information to order.

March 23, 2017:

March 2017 News Briefs

Social media